All studies
Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
F. Hoffmann-La Roche AG
Enrolment target
683
Start
26 Jun 2023
What is this study about?
Annualized rate of moderate and severe COPD exacerbations over the 52-week treatment period
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (16)
- —Hungary
- —Greece
- —Spain
- —Denmark
- —Sweden
- —France
- —Italy
- —Netherlands
- —Germany
- —Austria
- —Czechia
- —Belgium
+4 more sites — see the official record for the full list.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.